These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cytomegalovirus prophylaxis in pediatric renal transplant recipients. So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865 [No Abstract] [Full Text] [Related]
3. Cytomegalovirus infection in kidney transplantation: prophylaxis and management. Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286 [No Abstract] [Full Text] [Related]
4. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
5. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation. van Son WJ; van den Berg AP; The TH; Tegzess AM Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873 [No Abstract] [Full Text] [Related]
6. The problem of cytomegalovirus (CMV) prophylaxis in high-risk renal transplant recipients. Maiwald J; Sperschneider H; Stein G Nephrol Dial Transplant; 1996 Sep; 11(9):1897. PubMed ID: 8918658 [No Abstract] [Full Text] [Related]
7. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790 [TBL] [Abstract][Full Text] [Related]
8. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Ahsan N; Holman MJ; Yang HC Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699 [TBL] [Abstract][Full Text] [Related]